Co-Diagnostics Inc.

Co-Diagnostics, Inc Receives FDA Emergency Use Authorization for COVID-19 Test

Co-Diagnostics (CODX) to Post Q2 Earnings: What's in Store?

Logix Smart™ Coronavirus 2019 (COVID-19) Test Kit


At Co-Diagnostics, we are passionate about providing the most robust and innovative molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications, especially to those regions where pricing is paramount. Our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we are able to accomplish this faster and more economically, allowing for wider margins while still positioning Co-Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.

Logix Smart™ Coronavirus 2019 (COVID-19) Test Kit

The Logix Smart™ Coronavirus Disease 2019 (COVID-19) Test kit is an in vitro diagnostic test that uses our patented Co Primer™ technology for the qualitative detection of the RNA from SARS-CoV-2 coronavirus (COVID-19).

The test operates using a single step real-time reverse transcriptase-polymerase chain reaction (RT-PCR) process in lower respiratory tract fluids (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract fluids (e.g. nasopharyngeal and oropharyngeal swabs) from patients who meet the clinical criteria (e.g. signs and symptoms) for coronavirus disease 2019 (COVID-19) as established by WHO (WHO, 2020) and the US CDC (CDC, 2020) (e.g. fever, cough, shortness of breath, travel history to China).

  • Ready-to-use Master Mix, complete with RNaseP internal positive control to verify sample quality
  • Positive Control (PC), to verify the performance of the master mix
  • Nuclease-Free Water as a negative control, to verify master mix is free from contamination